Highlights

I think [I will use oral JAK inhibitors] in two ways. Number one, we’ve got folks that are needle averse, they just don’t want to inject and they really want to be on an oral medicine. So I think that population, obviously we would look to the JAKs because there’s really not anything else that is oral. And number two, depending on what else is out there – I mean right now we’re stuck. We really only have Dupixent and depending on what else is out there, you know it could be second- or even third-line depending on what happens to the IL-13s, but it could be a second- or third-line agent for someone that either there’s an AE with dupi or is just not optimally responding to Dupixent. So I don’t see the JAKs being first-line, but I do think it would be nice to have a second- or third-line agent.

The side effect profile is quite a bit more challenging with the JAKs than it is with dupi or the 13s, or even the 31s for that matter. You have to be much more careful with the oral JAKs.